JP5312720B2 - ポリアルキレングリコールを含むインスリン薬物−オリゴマー結合体の混合物、これらの使用、及びこれらの製造方法 - Google Patents

ポリアルキレングリコールを含むインスリン薬物−オリゴマー結合体の混合物、これらの使用、及びこれらの製造方法 Download PDF

Info

Publication number
JP5312720B2
JP5312720B2 JP2001316998A JP2001316998A JP5312720B2 JP 5312720 B2 JP5312720 B2 JP 5312720B2 JP 2001316998 A JP2001316998 A JP 2001316998A JP 2001316998 A JP2001316998 A JP 2001316998A JP 5312720 B2 JP5312720 B2 JP 5312720B2
Authority
JP
Japan
Prior art keywords
mixture
insulin
oligomer
component
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001316998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003113113A5 (enExample
JP2003113113A (ja
Inventor
ヌノキリ・エヌ・エクウリベ
クリストファー・エイチ・プライス
アスラム・エム・アンサリ
バラシンガム・ラダクリシュナン
エイミイ・エル・オーデンボウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of JP2003113113A publication Critical patent/JP2003113113A/ja
Publication of JP2003113113A5 publication Critical patent/JP2003113113A5/ja
Application granted granted Critical
Publication of JP5312720B2 publication Critical patent/JP5312720B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2001316998A 2001-06-04 2001-10-15 ポリアルキレングリコールを含むインスリン薬物−オリゴマー結合体の混合物、これらの使用、及びこれらの製造方法 Expired - Lifetime JP5312720B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/873,899 US6828297B2 (en) 2001-06-04 2001-06-04 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US09/873899 2001-06-04

Publications (3)

Publication Number Publication Date
JP2003113113A JP2003113113A (ja) 2003-04-18
JP2003113113A5 JP2003113113A5 (enExample) 2005-06-30
JP5312720B2 true JP5312720B2 (ja) 2013-10-09

Family

ID=25362553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001316998A Expired - Lifetime JP5312720B2 (ja) 2001-06-04 2001-10-15 ポリアルキレングリコールを含むインスリン薬物−オリゴマー結合体の混合物、これらの使用、及びこれらの製造方法

Country Status (14)

Country Link
US (3) US6828297B2 (enExample)
EP (1) EP1404178B1 (enExample)
JP (1) JP5312720B2 (enExample)
KR (1) KR20040004692A (enExample)
CN (1) CN1538809A (enExample)
AR (1) AR034356A1 (enExample)
AU (1) AU2002310291B2 (enExample)
BR (1) BR0106851A (enExample)
CA (1) CA2449426C (enExample)
DK (1) DK1404178T3 (enExample)
ES (1) ES2564820T3 (enExample)
MX (1) MXPA03011284A (enExample)
MY (1) MY139375A (enExample)
WO (1) WO2002098232A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AR033903A1 (es) 2001-05-21 2004-01-07 Inhale Therapeutic Syst Una composicion de insulina modificada quimicamente para la administracion pulmonar
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003022996A2 (en) 2001-09-07 2003-03-20 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7384914B2 (en) * 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2490243T3 (es) * 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
KR101225679B1 (ko) * 2005-07-08 2013-01-23 바이오콘 리미티드 인슐린 복합체의 제조
JP5047978B2 (ja) 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
CN100362916C (zh) * 2006-06-07 2008-01-23 南京医科大学 糜蛋白酶作为有机杀虫剂降解剂的应用
JP5048283B2 (ja) * 2006-07-20 2012-10-17 キヤノン株式会社 偏向器アレイ、描画装置およびデバイス製造方法
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
PL2074141T3 (pl) * 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
MX2009012789A (es) * 2007-06-01 2009-12-10 Novo Nordisk As Composiciones farmaceuticas no acuosas estables.
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
MY155612A (en) * 2008-07-14 2015-11-13 Biocon Ltd A method of synthesizing a substantially monodispersed mixture of oligomers
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
DE102008056086A1 (de) * 2008-11-06 2010-05-12 Gp Solar Gmbh Additiv für alkalische Ätzlösungen, insbesondere für Texturätzlösungen sowie Verfahren zu dessen Herstellung
US9060932B2 (en) 2009-07-09 2015-06-23 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
US8575124B2 (en) 2010-02-18 2013-11-05 Anthony P. Shuber Compositions and methods for treating cancer
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
JP6329486B2 (ja) 2011-10-21 2018-05-23 シーチェイド ファーマシューティカルズ，インコーポレーテッド 医薬組成物及びそれらの使用
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
EP2861065B1 (en) * 2012-06-18 2017-03-15 Basf Se Agroformulations containing a lactone based alkoxylate
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
CN104447981B (zh) * 2014-12-25 2015-07-08 重庆浦诺维生物科技有限公司 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
TWI839327B (zh) 2017-03-22 2024-04-21 美商建南德克公司 用於治療眼部病症之最佳化之抗體組合物
CN113087623A (zh) * 2021-04-13 2021-07-09 苏州昊帆生物股份有限公司 一种8-溴辛酸乙酯的合成方法
US20240315972A1 (en) 2021-07-12 2024-09-26 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1801575A (en) * 1927-11-04 1931-04-21 Delco Remy Corp Molding press
US3256153A (en) 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US4003792A (en) 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4044196A (en) 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2408387A2 (fr) 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4087390A (en) 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4093574A (en) 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
US4223163A (en) 1976-12-10 1980-09-16 The Procter & Gamble Company Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution
JPS53116315A (en) 1977-03-17 1978-10-11 Ueno Seiyaku Oyo Kenkyujo Kk Powder or granular containing improved sorbinic acid
US4100117A (en) 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
GB2051574B (en) 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4348387A (en) 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US4469681A (en) 1979-07-31 1984-09-04 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1144743B (it) 1981-07-09 1986-10-29 Mario Cane Apparecchio infusore di insulina perfezionato
US4698264A (en) 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4602043A (en) 1983-07-18 1986-07-22 Technology Unlimited Inc. Treatment for hypoglycemia
JPS6028025A (ja) * 1983-07-26 1985-02-13 Fuji Photo Film Co Ltd 磁気記録媒体
US4585754A (en) 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4717566A (en) 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4704394A (en) 1984-04-25 1987-11-03 Technology Unlimited, Inc. Treatment for hyperactivity
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US4761287A (en) 1984-05-03 1988-08-02 Technology Unlimited, Inc. Diabetes control by serotonin
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4622392A (en) 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
US4946828A (en) 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
SE457326B (sv) 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1339955C (en) 1986-10-14 1998-07-14 Richard Eugene Heiney Process for transforming a human insulin precursor to human insulin
GB8706313D0 (en) 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US5093198A (en) 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
US4822337A (en) 1987-06-22 1989-04-18 Stanley Newhouse Insulin delivery method and apparatus
DE3721721C1 (de) 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JPH01207320A (ja) 1988-02-15 1989-08-21 Daicel Chem Ind Ltd 芳香族ポリエーテルの製造方法
JPH01308231A (ja) 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
US5055300A (en) 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE3937797A1 (de) 1989-11-14 1991-05-16 Basf Ag Verfahren zur herstellung von polyetherglykolen
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DD297249A5 (de) 1990-08-07 1992-01-02 Veb Mineralwollewerk Flechtingen Bereich F/E Mineralwolle,De Verfahren zur automatischen ueberwachung des aushaertegrades an materialbahnen
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5468727A (en) 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
CA2108266C (en) 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
FR2675807B1 (fr) 1991-04-23 1994-07-01 Medgenix Group Sa Conjugue de calcitonine et de polyethylene glycol.
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
AU667316B2 (en) 1991-07-26 1996-03-21 Smithkline Beecham Corporation W/O microemulsions
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5693769A (en) 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
DE59309678D1 (de) 1992-01-17 1999-08-05 Alfatec Pharma Gmbh Verfahren zur Herstellung von Wirkstoff enthaltenden Pulvern, Granulaten oder Pellets mit einem Gerüst aus hydrophilen Makromolekülen und ihre Verwendung
GB9212511D0 (en) 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5262172A (en) 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5415872A (en) 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5420108A (en) 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
US6093391A (en) 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
AU7113594A (en) * 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
EP0792290B1 (en) 1993-09-17 2001-08-29 Novo Nordisk A/S Acylated insulin
SI0722434T1 (en) 1993-10-06 1998-12-31 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU692506B2 (en) 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
CA2190087C (en) 1994-05-10 2005-08-02 Piero Del Soldato Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
AU2455295A (en) 1994-05-20 1995-12-18 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
JPH10510516A (ja) 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
GB9424902D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5606038A (en) 1995-04-10 1997-02-25 Competitive Technologies, Inc. Amphiphilic polyene macrolide antibiotic compounds
EP0741187A2 (en) 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
WO1997014740A1 (en) * 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5639705A (en) 1996-01-19 1997-06-17 Arco Chemical Technology, L.P. Double metal cyanide catalysts and methods for making them
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5856369A (en) 1996-07-30 1999-01-05 Osi Specialties, Inc. Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts
DE19632440A1 (de) 1996-08-12 1998-02-19 Basf Ag Verfahren zur Herstellung von aus Polykationen aufgebauten, geformten Mischhydroxiden
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US5830918A (en) 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
DE69829763T2 (de) 1997-02-05 2006-04-13 F. Hoffmann-La Roche Ag Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
US6043214A (en) 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
BR9813111A (pt) 1997-10-24 2000-08-15 Lilly Co Eli Composições de insulina insolúveis
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6495514B1 (en) 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
JP2002518408A (ja) 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith

Also Published As

Publication number Publication date
US7470663B2 (en) 2008-12-30
EP1404178A1 (en) 2004-04-07
DK1404178T3 (en) 2016-03-07
BR0106851A (pt) 2003-04-08
CA2449426A1 (en) 2002-12-12
US20060199759A1 (en) 2006-09-07
US20030027748A1 (en) 2003-02-06
CN1538809A (zh) 2004-10-20
ES2564820T3 (es) 2016-03-29
KR20040004692A (ko) 2004-01-13
AR034356A1 (es) 2004-02-18
CA2449426C (en) 2013-12-03
WO2002098232A1 (en) 2002-12-12
AU2002310291B2 (en) 2007-09-20
JP2003113113A (ja) 2003-04-18
EP1404178A4 (en) 2010-05-26
MY139375A (en) 2009-09-30
US20040198949A1 (en) 2004-10-07
US6828297B2 (en) 2004-12-07
EP1404178B1 (en) 2016-01-20
US7084114B2 (en) 2006-08-01
MXPA03011284A (es) 2004-03-26

Similar Documents

Publication Publication Date Title
JP5312720B2 (ja) ポリアルキレングリコールを含むインスリン薬物−オリゴマー結合体の混合物、これらの使用、及びこれらの製造方法
AU2002310291A1 (en) Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP4272510B2 (ja) ポリアルキレングリコールを含むカルシトニン薬剤−オリゴマー抱合体の混合物、その使用、およびその製造方法
US7312192B2 (en) Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7368260B2 (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
JP2004534783A (ja) ポリアルキレングリコールを含む成長ホルモン剤−オリゴマー抱合体の混合物、それらの使用、およびそれらの製造方法
JP4318546B2 (ja) インスリンポリペプチド−オリゴマーコンジュゲートの合成方法、ならびにプロインスリンポリペプチド−オリゴマーコンジュゲートおよびその合成方法
US7166571B2 (en) Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
CN1080575C (zh) 结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
HK1082182A (en) Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
HK1082182B (en) Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2002310278A1 (en) Mixtures of growth hormone drug-oligomer conjugates compromising polyalkylene glycol, uses thereof, and methods of making same

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041015

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20080523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081022

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081027

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090109

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090618

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120514

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130315

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130703

R150 Certificate of patent or registration of utility model

Ref document number: 5312720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250